How should a patient on Eliquis (apixaban) be managed after a head injury?

Management of Head Injury in Patients on Eliquis (Apixaban)

All patients on Eliquis who sustain a head injury should receive an immediate CT scan of the head, and if neurologically intact with a negative initial CT, can be safely discharged without mandatory repeat imaging or prolonged observation. 1

Initial Assessment and Imaging

• Obtain immediate head CT for all patients on Eliquis presenting with head injury, regardless of severity, as anticoagulation increases both the risk of intracranial hemorrhage (ICH) and associated mortality. 1
• The threshold for imaging should be very low given that NOACs (including apixaban) carry a 2.6% ICH risk compared to 1.5% in non-anticoagulated patients after blunt head trauma. 1
• Initial CT has high negative predictive value for clinically significant acute ICH. 2

Management Based on Initial CT Results

If Initial CT Shows Intracranial Hemorrhage:

• Administer andexanet alfa as the specific reversal agent for apixaban. 3
• Dosing depends on timing and dose of last apixaban intake:
  • Low-dose regimen: 400 mg IV bolus followed by 4 mg/min infusion for 120 minutes if last apixaban dose ≤5 mg taken <8 hours prior, or any dose taken ≥8 hours prior. 3
  • High-dose regimen: 800 mg IV bolus followed by 8 mg/min infusion for 120 minutes if last apixaban dose >5 mg taken <8 hours prior. 3
• If andexanet alfa unavailable, administer four-factor prothrombin complex concentrate (PCC) or activated PCC as alternative. 3
• Consider activated charcoal if ingestion occurred within 2-4 hours. 3
• Discontinue Eliquis in patients with active pathological hemorrhage. 4

If Initial CT is Negative:

• Patients who are neurologically intact can be safely discharged without repeat CT or mandatory observation admission. 1
• The risk of delayed ICH in neurologically intact patients on NOACs is extremely low (<1% requiring neurosurgical intervention). 1
• In the largest multicenter study of 916 NOAC patients with repeat CT at 24 hours, delayed ICH occurred in only 1.5%, with no deaths or neurosurgical interventions required. 1
• Among 314 patients on DOACs (primarily apixaban and rivaroxaban) with negative initial CT, only 0.95% developed delayed ICH, and none required neurosurgical intervention. 2

Special Considerations

Observation Period (Optional):

• Brief observation (4-6 hours) may be considered but is not mandatory, as studies show lack of ICH or neurologic deterioration during this period. 1
• Most delayed ICH events are not clinically significant and rarely necessitate neurosurgical intervention. 1

Concomitant Antiplatelet Use:

• Exercise greater caution in patients on dual therapy (apixaban plus antiplatelet agents), particularly aspirin in elderly patients. 1
• Elderly patients (≥65 years) on aspirin with high-risk features (loss of consciousness, amnesia, or GCS <15) may warrant observation or repeat imaging. 1
• In one study, 2 of 3 patients who developed delayed ICH were on concomitant antiplatelet medication. 2

Discharge Instructions:

• Provide clear return precautions given up to 5% risk of delayed ICH. 1
• Patients should return immediately for: worsening headache, confusion, weakness, numbness, vision changes, seizures, or persistent vomiting. 1
• Ensure patients have adequate social support for home observation, particularly those requiring physical or cognitive assistance. 1

Anticoagulation Management:

• No strong evidence supports withholding apixaban after negative CT if patient is not supratherapeutic. 1
• Balance the risk of repeat trauma against thromboembolic risk from the underlying indication for anticoagulation. 1
• When restarting anticoagulation after ICH, consider timing based on bleeding stability (typically 7-12 days for major bleeds, though earlier resumption may be needed for high thrombotic risk). 3, 5

Common Pitfalls to Avoid

• Do not routinely admit all anticoagulated patients with head injury for observation alone if initial CT is negative and neurologic exam is normal. 1
• Do not assume all DOACs carry equal risk—apixaban has demonstrated comparable or potentially superior safety to aspirin regarding ICH risk in some contexts. 6
• Do not delay reversal agent administration when ICH is present, as the pharmacodynamic effect of apixaban persists for at least 24 hours (two half-lives). 4
• Do not use standard coagulation tests (PT, INR, aPTT) to monitor reversal with PCCs, as these are not useful for apixaban. 3